These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37861026)

  • 1. The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
    Martín-García D; Téllez T; Redondo M; García-Aranda M
    Curr Med Chem; 2024; 31(39):6487-6509. PubMed ID: 37861026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
    Ständer S; Yosipovitch G
    Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Robinson P; Coveñas R; Muñoz M
    Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
    Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
    PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the research and application of neurokinin-1 receptor antagonists.
    Hong X; Ma J; Zheng S; Zhao G; Fu C
    J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
    Muñoz M; Rosso M; Coveñas R
    Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
    Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer progression and substance P.
    Coveñas R; Muñoz M
    Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.
    Yamamoto K; Asano K; Tasaka A; Ogura Y; Kim S; Ito Y; Yamatodani A
    Br J Pharmacol; 2014 Jun; 171(11):2888-99. PubMed ID: 24641692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of substance P in the growth of brain tumors.
    Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
    Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
    Muñoz M; Coveñas R
    Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
    Muñoz M; Coveñas R
    World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.